Summary & Overview
HCPCS C2637: Ytterbium-169 Brachytherapy Source, Non-Stranded
HCPCS Level II code C2637 represents a single non‑stranded brachytherapy source containing ytterbium‑169. This supply code is used when documenting and billing for individual radioactive seeds or sources delivered for internal radiation therapy. Its accurate use matters nationally because brachytherapy remains an important modality in cancer care and supply codes affect reimbursement, inventory tracking, and clinical documentation for radiation oncology providers.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ytterbium‑169 brachytherapy sources, typical sites of service where these sources are used, and the elements that influence coding and billing for single-source supplies. The publication also lays out common modifiers and payer considerations, benchmarking expectations where available, and recent policy developments relevant to HCPCS supply codes.
The content is intended for billing managers, radiation oncology clinicians, and revenue cycle staff seeking concise guidance on how this HCPCS Level II code is applied in practice and how payer policies can affect claim adjudication and documentation requirements.
Billing Code Overview
HCPCS Level II code C2637 denotes a brachytherapy source, non-stranded, ytterbium-169, per source. This code describes an individual radioactive source used in brachytherapy treatments that employ ytterbium-169 as the radionuclide.
-
Service type: Brachytherapy source supply for internal radiation therapy
-
Typical site of service: Radiation oncology departments, hospital-based outpatient departments, and freestanding radiation treatment centers
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing interstitial or intracavitary brachytherapy for a localized malignancy (for example, prostate, gynecologic, or head and neck cancer) where short-range, low-energy radiation using ytterbium-169 sources is indicated. The patient is evaluated in a radiation oncology clinic, with multidisciplinary planning involving a radiation oncologist and medical physicist. Treatment planning includes imaging (CT/MRI), dose calculation, and selection of non-stranded C2637 ytterbium-169 sources. On the day of implantation, the patient is brought to a procedure suite or operating room for anesthetic management (local, regional, or general depending on site and complexity). The radiation oncology team places applicators or needles under image guidance, loads the prescribed number of C2637 sources, documents source inventory, and arranges safe disposal/return of unused sources. Typical sites of service are a hospital outpatient department, ambulatory surgery center, or radiation oncology treatment suite. Post-procedure workflow includes radiation safety checks, radiation treatment delivery if using an afterloading device, clinical follow-up for wound care and toxicity assessment, and coordination with payors for device and procedure coverage documentation (including appropriate modifier use).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |